Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative

As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast (Edinburgh) 2025-04, Vol.80, p.103887, Article 103887
Hauptverfasser: Henkel, Jan, Laner, Andreas, Locher, Melanie, Wohlfrom, Tobias, Neitzel, Birgit, Becker, Kerstin, Neuhann, Teresa, Abicht, Angela, Steinke-Lange, Verena, Klink, Barbara, Eichhorn, Birgit, Schmidt, Winfried, Berner, Daniel, Teubert, Anna, Holtorf, Anne, Heinrich, Sarah, Wildhardt, Gabriele, Schulze, Martin, von der Heyden, Laura, Hörtnagel, Konstanze, Steinberger, Daniela, Kleier, Saskia, Lorenz, Peter, Glaubitz, Ralf, Biskup, Saskia, Holinski-Feder, Elke
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 103887
container_title Breast (Edinburgh)
container_volume 80
creator Henkel, Jan
Laner, Andreas
Locher, Melanie
Wohlfrom, Tobias
Neitzel, Birgit
Becker, Kerstin
Neuhann, Teresa
Abicht, Angela
Steinke-Lange, Verena
Klink, Barbara
Eichhorn, Birgit
Schmidt, Winfried
Berner, Daniel
Teubert, Anna
Holtorf, Anne
Heinrich, Sarah
Wildhardt, Gabriele
Schulze, Martin
von der Heyden, Laura
Hörtnagel, Konstanze
Steinberger, Daniela
Kleier, Saskia
Lorenz, Peter
Glaubitz, Ralf
Biskup, Saskia
Holinski-Feder, Elke
description As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network. We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes. At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS. These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer. •Expanded gene panel testing for hereditary cancer increases the diagnostic yield.•Disease specific gene panels overlook 1 % of patients with a high-risk TRS.•Joint data analysis of different German diagnostic laboratories.
doi_str_mv 10.1016/j.breast.2025.103887
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3159798259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960977625000165</els_id><sourcerecordid>3159798259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2027-24ec7d2e38ae494555e1c200a81fe7465271143c34d083015ae1e1bc7b14bdb63</originalsourceid><addsrcrecordid>eNp9UctuGyEURVGqxE3zB1XEMpU6LgwwwCZSYqVJq6hZtFkjBu7UWPNwALvKp_RvizVpl12B4DzuuQeh95QsKaHNp82yjWBTXtakFuWJKSWP0IIKVleMKHKMFkQ3pNJSNqfobUobQohmjTpBp0wrwRVRC_T76xTGjO1o-5cUEp46_BPi0IcRymWEHBz2NlvcxWnA0x4irvXHooSdTZDwr5DXOO3SFlwGj9cQwYds4wuepyvKvtBsDHYslNEVgcv7m8fVB2wT3tqYD5Z5Dfjb9fe7WxzGkIPNYQ_v0JvO9gnOX88z9PT59sfqvnp4vPuyun6oXAkuq5qDk74GpixwzYUQQMsPsYp2IHkjakkpZ45xTxQjVFigQFsnW8pb3zbsDF3Outs4Pe8gZTOE5KDv7QjTLhlGhZZa1UIXKJ-hLk4pRejMNoahhDWUmEMpZmPm2OZQiplLKbSLV4ddO4D_R_rbQgFczQAoOfcBokkuQNmVD7Hs1fgp_N_hD7ECntc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3159798259</pqid></control><display><type>article</type><title>Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative</title><source>DOAJ Directory of Open Access Journals</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Henkel, Jan ; Laner, Andreas ; Locher, Melanie ; Wohlfrom, Tobias ; Neitzel, Birgit ; Becker, Kerstin ; Neuhann, Teresa ; Abicht, Angela ; Steinke-Lange, Verena ; Klink, Barbara ; Eichhorn, Birgit ; Schmidt, Winfried ; Berner, Daniel ; Teubert, Anna ; Holtorf, Anne ; Heinrich, Sarah ; Wildhardt, Gabriele ; Schulze, Martin ; von der Heyden, Laura ; Hörtnagel, Konstanze ; Steinberger, Daniela ; Kleier, Saskia ; Lorenz, Peter ; Glaubitz, Ralf ; Biskup, Saskia ; Holinski-Feder, Elke</creator><creatorcontrib>Henkel, Jan ; Laner, Andreas ; Locher, Melanie ; Wohlfrom, Tobias ; Neitzel, Birgit ; Becker, Kerstin ; Neuhann, Teresa ; Abicht, Angela ; Steinke-Lange, Verena ; Klink, Barbara ; Eichhorn, Birgit ; Schmidt, Winfried ; Berner, Daniel ; Teubert, Anna ; Holtorf, Anne ; Heinrich, Sarah ; Wildhardt, Gabriele ; Schulze, Martin ; von der Heyden, Laura ; Hörtnagel, Konstanze ; Steinberger, Daniela ; Kleier, Saskia ; Lorenz, Peter ; Glaubitz, Ralf ; Biskup, Saskia ; Holinski-Feder, Elke</creatorcontrib><description>As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network. We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes. At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS. These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer. •Expanded gene panel testing for hereditary cancer increases the diagnostic yield.•Disease specific gene panels overlook 1 % of patients with a high-risk TRS.•Joint data analysis of different German diagnostic laboratories.</description><identifier>ISSN: 0960-9776</identifier><identifier>ISSN: 1532-3080</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1016/j.breast.2025.103887</identifier><identifier>PMID: 39854808</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Gene panel testing ; Genetic predisposition to disease ; Genetic testing ; Genetic variation ; Hereditary ; Hereditary breast and ovarian cancer syndrome ; High-throughput nucleotide sequencing ; Neoplastic syndromes ; Retrospective studies ; Risk assessment</subject><ispartof>Breast (Edinburgh), 2025-04, Vol.80, p.103887, Article 103887</ispartof><rights>2025 The Authors</rights><rights>Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2027-24ec7d2e38ae494555e1c200a81fe7465271143c34d083015ae1e1bc7b14bdb63</cites><orcidid>0000-0003-3798-5977</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0960977625000165$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39854808$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henkel, Jan</creatorcontrib><creatorcontrib>Laner, Andreas</creatorcontrib><creatorcontrib>Locher, Melanie</creatorcontrib><creatorcontrib>Wohlfrom, Tobias</creatorcontrib><creatorcontrib>Neitzel, Birgit</creatorcontrib><creatorcontrib>Becker, Kerstin</creatorcontrib><creatorcontrib>Neuhann, Teresa</creatorcontrib><creatorcontrib>Abicht, Angela</creatorcontrib><creatorcontrib>Steinke-Lange, Verena</creatorcontrib><creatorcontrib>Klink, Barbara</creatorcontrib><creatorcontrib>Eichhorn, Birgit</creatorcontrib><creatorcontrib>Schmidt, Winfried</creatorcontrib><creatorcontrib>Berner, Daniel</creatorcontrib><creatorcontrib>Teubert, Anna</creatorcontrib><creatorcontrib>Holtorf, Anne</creatorcontrib><creatorcontrib>Heinrich, Sarah</creatorcontrib><creatorcontrib>Wildhardt, Gabriele</creatorcontrib><creatorcontrib>Schulze, Martin</creatorcontrib><creatorcontrib>von der Heyden, Laura</creatorcontrib><creatorcontrib>Hörtnagel, Konstanze</creatorcontrib><creatorcontrib>Steinberger, Daniela</creatorcontrib><creatorcontrib>Kleier, Saskia</creatorcontrib><creatorcontrib>Lorenz, Peter</creatorcontrib><creatorcontrib>Glaubitz, Ralf</creatorcontrib><creatorcontrib>Biskup, Saskia</creatorcontrib><creatorcontrib>Holinski-Feder, Elke</creatorcontrib><title>Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative</title><title>Breast (Edinburgh)</title><addtitle>Breast</addtitle><description>As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network. We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes. At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS. These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer. •Expanded gene panel testing for hereditary cancer increases the diagnostic yield.•Disease specific gene panels overlook 1 % of patients with a high-risk TRS.•Joint data analysis of different German diagnostic laboratories.</description><subject>Gene panel testing</subject><subject>Genetic predisposition to disease</subject><subject>Genetic testing</subject><subject>Genetic variation</subject><subject>Hereditary</subject><subject>Hereditary breast and ovarian cancer syndrome</subject><subject>High-throughput nucleotide sequencing</subject><subject>Neoplastic syndromes</subject><subject>Retrospective studies</subject><subject>Risk assessment</subject><issn>0960-9776</issn><issn>1532-3080</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNp9UctuGyEURVGqxE3zB1XEMpU6LgwwwCZSYqVJq6hZtFkjBu7UWPNwALvKp_RvizVpl12B4DzuuQeh95QsKaHNp82yjWBTXtakFuWJKSWP0IIKVleMKHKMFkQ3pNJSNqfobUobQohmjTpBp0wrwRVRC_T76xTGjO1o-5cUEp46_BPi0IcRymWEHBz2NlvcxWnA0x4irvXHooSdTZDwr5DXOO3SFlwGj9cQwYds4wuepyvKvtBsDHYslNEVgcv7m8fVB2wT3tqYD5Z5Dfjb9fe7WxzGkIPNYQ_v0JvO9gnOX88z9PT59sfqvnp4vPuyun6oXAkuq5qDk74GpixwzYUQQMsPsYp2IHkjakkpZ45xTxQjVFigQFsnW8pb3zbsDF3Outs4Pe8gZTOE5KDv7QjTLhlGhZZa1UIXKJ-hLk4pRejMNoahhDWUmEMpZmPm2OZQiplLKbSLV4ddO4D_R_rbQgFczQAoOfcBokkuQNmVD7Hs1fgp_N_hD7ECntc</recordid><startdate>202504</startdate><enddate>202504</enddate><creator>Henkel, Jan</creator><creator>Laner, Andreas</creator><creator>Locher, Melanie</creator><creator>Wohlfrom, Tobias</creator><creator>Neitzel, Birgit</creator><creator>Becker, Kerstin</creator><creator>Neuhann, Teresa</creator><creator>Abicht, Angela</creator><creator>Steinke-Lange, Verena</creator><creator>Klink, Barbara</creator><creator>Eichhorn, Birgit</creator><creator>Schmidt, Winfried</creator><creator>Berner, Daniel</creator><creator>Teubert, Anna</creator><creator>Holtorf, Anne</creator><creator>Heinrich, Sarah</creator><creator>Wildhardt, Gabriele</creator><creator>Schulze, Martin</creator><creator>von der Heyden, Laura</creator><creator>Hörtnagel, Konstanze</creator><creator>Steinberger, Daniela</creator><creator>Kleier, Saskia</creator><creator>Lorenz, Peter</creator><creator>Glaubitz, Ralf</creator><creator>Biskup, Saskia</creator><creator>Holinski-Feder, Elke</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3798-5977</orcidid></search><sort><creationdate>202504</creationdate><title>Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative</title><author>Henkel, Jan ; Laner, Andreas ; Locher, Melanie ; Wohlfrom, Tobias ; Neitzel, Birgit ; Becker, Kerstin ; Neuhann, Teresa ; Abicht, Angela ; Steinke-Lange, Verena ; Klink, Barbara ; Eichhorn, Birgit ; Schmidt, Winfried ; Berner, Daniel ; Teubert, Anna ; Holtorf, Anne ; Heinrich, Sarah ; Wildhardt, Gabriele ; Schulze, Martin ; von der Heyden, Laura ; Hörtnagel, Konstanze ; Steinberger, Daniela ; Kleier, Saskia ; Lorenz, Peter ; Glaubitz, Ralf ; Biskup, Saskia ; Holinski-Feder, Elke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2027-24ec7d2e38ae494555e1c200a81fe7465271143c34d083015ae1e1bc7b14bdb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Gene panel testing</topic><topic>Genetic predisposition to disease</topic><topic>Genetic testing</topic><topic>Genetic variation</topic><topic>Hereditary</topic><topic>Hereditary breast and ovarian cancer syndrome</topic><topic>High-throughput nucleotide sequencing</topic><topic>Neoplastic syndromes</topic><topic>Retrospective studies</topic><topic>Risk assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henkel, Jan</creatorcontrib><creatorcontrib>Laner, Andreas</creatorcontrib><creatorcontrib>Locher, Melanie</creatorcontrib><creatorcontrib>Wohlfrom, Tobias</creatorcontrib><creatorcontrib>Neitzel, Birgit</creatorcontrib><creatorcontrib>Becker, Kerstin</creatorcontrib><creatorcontrib>Neuhann, Teresa</creatorcontrib><creatorcontrib>Abicht, Angela</creatorcontrib><creatorcontrib>Steinke-Lange, Verena</creatorcontrib><creatorcontrib>Klink, Barbara</creatorcontrib><creatorcontrib>Eichhorn, Birgit</creatorcontrib><creatorcontrib>Schmidt, Winfried</creatorcontrib><creatorcontrib>Berner, Daniel</creatorcontrib><creatorcontrib>Teubert, Anna</creatorcontrib><creatorcontrib>Holtorf, Anne</creatorcontrib><creatorcontrib>Heinrich, Sarah</creatorcontrib><creatorcontrib>Wildhardt, Gabriele</creatorcontrib><creatorcontrib>Schulze, Martin</creatorcontrib><creatorcontrib>von der Heyden, Laura</creatorcontrib><creatorcontrib>Hörtnagel, Konstanze</creatorcontrib><creatorcontrib>Steinberger, Daniela</creatorcontrib><creatorcontrib>Kleier, Saskia</creatorcontrib><creatorcontrib>Lorenz, Peter</creatorcontrib><creatorcontrib>Glaubitz, Ralf</creatorcontrib><creatorcontrib>Biskup, Saskia</creatorcontrib><creatorcontrib>Holinski-Feder, Elke</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henkel, Jan</au><au>Laner, Andreas</au><au>Locher, Melanie</au><au>Wohlfrom, Tobias</au><au>Neitzel, Birgit</au><au>Becker, Kerstin</au><au>Neuhann, Teresa</au><au>Abicht, Angela</au><au>Steinke-Lange, Verena</au><au>Klink, Barbara</au><au>Eichhorn, Birgit</au><au>Schmidt, Winfried</au><au>Berner, Daniel</au><au>Teubert, Anna</au><au>Holtorf, Anne</au><au>Heinrich, Sarah</au><au>Wildhardt, Gabriele</au><au>Schulze, Martin</au><au>von der Heyden, Laura</au><au>Hörtnagel, Konstanze</au><au>Steinberger, Daniela</au><au>Kleier, Saskia</au><au>Lorenz, Peter</au><au>Glaubitz, Ralf</au><au>Biskup, Saskia</au><au>Holinski-Feder, Elke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative</atitle><jtitle>Breast (Edinburgh)</jtitle><addtitle>Breast</addtitle><date>2025-04</date><risdate>2025</risdate><volume>80</volume><spage>103887</spage><pages>103887-</pages><artnum>103887</artnum><issn>0960-9776</issn><issn>1532-3080</issn><eissn>1532-3080</eissn><abstract>As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network. We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes. At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS. These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer. •Expanded gene panel testing for hereditary cancer increases the diagnostic yield.•Disease specific gene panels overlook 1 % of patients with a high-risk TRS.•Joint data analysis of different German diagnostic laboratories.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>39854808</pmid><doi>10.1016/j.breast.2025.103887</doi><orcidid>https://orcid.org/0000-0003-3798-5977</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0960-9776
ispartof Breast (Edinburgh), 2025-04, Vol.80, p.103887, Article 103887
issn 0960-9776
1532-3080
1532-3080
language eng
recordid cdi_proquest_miscellaneous_3159798259
source DOAJ Directory of Open Access Journals; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Gene panel testing
Genetic predisposition to disease
Genetic testing
Genetic variation
Hereditary
Hereditary breast and ovarian cancer syndrome
High-throughput nucleotide sequencing
Neoplastic syndromes
Retrospective studies
Risk assessment
title Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T09%3A20%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Joint%20analysis%20of%20germline%20genetic%20data%20from%20over%2029,000%20cases%20with%20suspected%20hereditary%20breast%20and%20ovarian%20cancer%20(HBOC)%20as%20part%20of%20the%20NASGE%20initiative&rft.jtitle=Breast%20(Edinburgh)&rft.au=Henkel,%20Jan&rft.date=2025-04&rft.volume=80&rft.spage=103887&rft.pages=103887-&rft.artnum=103887&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1016/j.breast.2025.103887&rft_dat=%3Cproquest_cross%3E3159798259%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3159798259&rft_id=info:pmid/39854808&rft_els_id=S0960977625000165&rfr_iscdi=true